2015
Monday Mon
Public-Private Partnerships: What is the Role of Technology of Biosecurity?
Does Biotechnology Affect Policy? Does Policy Affect the Technology?
Dr. Scannon will present three short talks discussing the above questions. Dr. Scannon will also discuss the issue of responsiveness as a key challenge to incident response, as it relates to rapid development of counter-measures for an unknown threat. The organizational issues concerning Strategic National Stockpile, unified national strategy, centralized leadership, adequate and sustained funding in biosecurity will also be discussed.
Location
291 Campus Dr.
Palo Alto, CA 94305
USA
Li Ka Shing Learning & Knowledge Center (LKSC)
291 Campus Dr.Palo Alto, CA 94305
Speaker
Patrick Scannon, MD, PhD; CEO of XOMA
Patrick J. Scannon, M.D., Ph.D. is one of the founders and the CEO of XOMA, Inc. XOMA is a biotechnology company focused on the discovery, development and manufacturing of monoclonal antibody-based therapeutics for unmet medical needs, including the BioSecurity market. XOMA’s monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than $1 billion in annual sales and for which XOMA received substantial royalties. The company also has a strong track record of product discovery and development collaborations with pharmaceutical and biotechnology companies and the U.S. government, and has licensed certain of its fundamental technologies to numerous pharma and biotech companies.
In 2007, Dr. Scannon was invited to join the newly formed National Biodefense Science Board, reporting to the Secretary of the Department of Health and Human Services. He also serves on the Defense Sciences Research Council for the Defense Advanced Research Projects Agency (DARPA) and on the Threat Reduction Advisory Committee for the Department of Defense. From 1979 until 1981, Dr. Scannon was a clinical research scientist at the Letterman Army Institute of Research in San Francisco. A Board-certified internist, Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and an M.D. from the Medical College of Georgia.